The cancer tissue diagnostic market has exhibited an ascending trend, where its value is estimated to go from US$ 15,302.2 million in 2024 to US$ 23,516.2 million in 2034. Adoption of cancer tissue diagnostics is exhibiting a CAGR of 4.5% from 2024 to 2034. The market was valued at US$ 14,651.0 million in 2023 and is anticipated to exhibit a y-o-y growth of 4.4% in 2024.
| Attributes | Key Insights |
|---|---|
| Base Value (2023) | US$ 14,651.0 million |
| Global Cancer Tissue Diagnostic Market Size (2024E) | US$ 15,302.2 million |
| Cancer Tissue Diagnostic Market Value (2034F) | US$ 23,516.2 million |
| Value-based CAGR (2024 to 2034) | 4.5% |
The market witnessed remarkable expansion in recent years due to the growing demand for high-throughput cancer tissue diagnostic kits. This increase in demand for cancer tissue diagnostics is due to its ability to quickly process a large volume of samples and provide effective diagnostic solutions.
Growing demand for genetic testing and analysis of personalized medicine and genomic research & developments is further anticipating market growth. The market is set to surge as several pharmaceutical companies invest in developing and manufacturing sophisticated cancer tissue diagnostics.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global cancer tissue diagnostic market recorded a historical CAGR of 3.4% from 2019 to 2023. Historical factors such as the dependency on hospitals, specialty centers, and diagnostics centers have contributed to the development of innovative technologies in cancer tissue diagnostics. Innovative technologies have significantly enhanced the efficiency of diagnostics processes in pharmacogenomics, genetic disorders, and oncology disease diagnosis, leading to increased applications.
Looking forward to the future, the market is projected to grow significantly. The shift is majorly attributed to the rising preference of healthcare professionals for early diagnosis and prognosis of cancer. Growing emphasis on personalized cancer treatments and the development of targeted therapies is fueling growth of cancer tissue diagnostics kits.
Strategic initiatives such as mergers and acquisitions taken by manufacturing companies to develop new products are projected to further propel market growth. The rapid development of technology and innovative diagnostic methodologies have prompted market players to boost their product offerings and enhance their market presence.
For instance, in March 2021, United States-based Agilent Technologies Inc. acquired Resolution Bioscience to strengthen its leadership position in cancer diagnostics. Hence, these strategic collaborations and acquisitions aim to develop innovative solutions to address emerging market needs and stay at the forefront of innovations in cancer diagnostics.
The rising prevalence of different types of cancers among the general population has majorly contributed to the growing adoption of cancer tissue diagnosis in the healthcare fraternity. Rising demand for technologically progressed diagnostics for effective diagnosis has encouraged manufacturers to develop diagnostic kits that are efficient and affordable. This thriving landscape of clinical trials in research & development of novel cancer diagnostics is set to contribute to the growth of the market by 2034.
Growing application of cutting-edge molecular diagnostics technologies, such as next-generation sequencing and liquid biopsy techniques for accurate, personalized, and effective diagnosis, further augment the market. The rapid and comprehensive analysis of patient genetic material with unprecedented accuracy and depth contributes to its surging adoption. Other advantages, such as the ability of liquid biopsies to monitor disease progression over time and the potential for early detection & treatment adjustment, propel market growth.
Favorable initiatives taken by the government for the manufacturing and exporting of diagnostic kits & reagents have also played a pivotal role in the growth of the market. For instance, India has lifted export restrictions on diagnostic kits and reagents, including equipment such as cancer tissue diagnostics kits.
Principal Consultant
Several cancer diagnostics manufacturing companies and healthcare facilities have seen a sizeable gap between the availability of skilled professionals and their needs. This shortage of experienced and skilled individuals, along with limited awareness, is hampering the market. Inadequate healthcare infrastructure and primary healthcare facilities, particularly in rural areas, are further limiting the accessibility of cancer tissue diagnostics.
The research study indicates that there are some underexplored fields of diagnostic product manufacturers in key countries. In accordance with the forecast, China and India are going to be a sizable area for cancer tissue diagnostic manufacturers to grow. But, the United States, United Kingdom, and Germany are taking advantage of their established markets, which means their growth rates are stable.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 3.1% |
| China | 6.8% |
| Germany | 2.5% |
| United Kingdom | 2.1% |
| India | 5.8% |
The United States dominates the global market with a 91.7% share in 2023 and is projected to continue experiencing stable growth throughout the forecast period. Increasing prevalence of cancer among the general population is fueling the adoption of cancer tissue diagnostics in the country, pushing market growth.
For instance, according to the statistics published by the Centers for Disease Control and Prevention in April 2023, in 2019, around 224,733 new cases of prostate cancer were reported in the United States. Increasing prevalence of cancer in the country is largely due to genetic complexity, rising drug use among the millennial population, and sedentary lifestyle of the general population.
China is set to lead the market at a CAGR of 6.8% through 2034. Research universities' increasing investment in cancer diagnosis programs and precision medicine research is propelling market growth in China.
The growing focus of regulatory bodies on initiating new programs for screening genetic mutations among individuals in China is contributing to the market's growth. For instance, according to a journal published by Precision Cancer Medicine in 2021, Fudan University Shanghai Cancer Center (FUSCC) in China launched a new program for screening BRCA mutations using next-generation sequencing (NGS).
In 2023, Germany held a significant global market share of 25% and is anticipated to maintain considerable growth over the forecast period. Increasing awareness of the surging prevalence of breast cancer among women in Germany is propelling growth of the tissue diagnostics product market.
Increasing prevalence of breast cancer has led to a surging adoption of cancer tissue diagnostics products, prompting manufacturers to broaden their distribution channels. For instance, in April 2023, Cerca Biotech collaborated with Sysmex Europe, a laboratory equipment supplier in Germany, to distribute their RT-qPCR molecular breast cancer assay in 13 European markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The segmented cancer tissue diagnostic analysis is mentioned in the following subsection. Based on comprehensive studies, the molecular diagnostics test kits segment is leading the product type category. Similarly, the breast cancer segment is commanding the cancer type category.
| Product Type | Molecular Diagnostics Test Kits |
|---|---|
| Value CAGR (2024 to 2034) | 3.7% |
The molecular diagnostics test kit segment is set to lead the market, accounting for 42.7% market share in 2023, and is projected to grow at a substantial rate by 2034. Growth of molecular diagnostic test kits is propelled by increasing demand for personalized medicine, genomic research developments, and rapid diagnostic solutions. Moreover, their ability to conduct essential testing of infectious diseases with rapid and accurate results anticipates its growth.
| Cancer Type | Value CAGR (2024 to 2034) |
|---|---|
| Breast Cancer | 5.1% |
| Lung Cancer | 4.5% |
The breast cancer segment held a market share of 22.7% in 2023 and is projected to continue experiencing high growth throughout the forecast period. The rising prevalence of breast cancer among women due to aging, genetic mutations, and changing lifestyles has become a notable concern in recent years. Increasing prevalence of breast cancer is surging growth of the breast cancer segment through the increased use of cancer tissue diagnostics.
| End-user | Value CAGR (2024 to 2034) |
|---|---|
| Hospitals | 5.4% |
| Specialty Centers | 4.1% |
The hospital segment dominated the market and held a market share of 34.4% in 2023. Increasing awareness of different types of cancers has contributed to rising patient footfall in hospital facilities for routine check-ups. In addition, continuously improving healthcare infrastructure in developed and developing countries propels its expansion.
In the dynamic market landscape, companies emphasize launching new products to broaden their portfolio. Moreover, they are focusing on strategic collaborations and partnerships to address evolving market demands and extend their geographic footprint. Leading companies are directed toward product launches and developments to strengthen their market hold.
For instance
The market is set to reach US$ 15,302.2 million in 2024.
Demand for cancer tissue diagnostics is slated to rise at a 4.5% CAGR by 2034.
The market is set to reach US$ 23,516.2 million in 2034.
Abbott Laboratories, F. Hoffman-La Roche Ltd., and Thermo Fisher Scientific Inc. are the key players.
Breast cancer segment is estimated to hold a significant market share in 2024.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development/Innovation Trends
4. Value-Added Insights
4.1. Product Adoption/ Usage Analysis, by Region
4.2. Disease Epidemiology
4.3. Regulatory Scenario
4.4. Reimbursement Scenario
4.5. PESTLE Analysis
4.6. PORTER Analysis
4.7. Value Chain Analysis
4.8. Unmet Needs
4.9. Key Industry Developments
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure
5.1.2. R&D Funding Outlook, By Region
5.1.3. R and D Funding Outlook, By Country
5.2. Forecast Factors - Relevance and Impact
5.2.1. Increasing Investments in R and D Activities
5.2.2. Increasing Cancer Prevalence
5.2.3. Increase in Demand of Personalized Medicine
5.2.4. Advancements in Diagnostic Technologies
5.2.5. Cancer Survivorship Programs
5.2.6. Changing Regulatory Dynamics
5.2.7. Biomarker Discovery and Validation
5.2.8. Market Consolidation Activities
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market Value (US$ million) Analysis, 2019 to 2023
6.2. Current and Future Market Value (US$ million) Projections, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ million) Analysis By Product type, 2019 to 2023
7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Product type, 2024 to 2034
7.3.1. In Situ Hybridization (ISH) Test Kits
7.3.1.1. Fluorescent In Situ Hybridization (FISH) Kits
7.3.1.2. Chromogenic In Situ Hybridization (CISH) Kits
7.3.2. Molecular Diagnostics Test Kits
7.3.2.1. Polymerase Chain Reaction (PCR) Kits
7.3.2.2. Next-generation Sequencing (NGS) Kits
7.3.3. Companion Diagnostics Test Kits
7.3.3.1. Genetic Testing Kits
7.3.3.2. Biomarker Testing Kits
7.3.4. Immunohistochemistry (IHC) Test Kits
7.4. Market Attractiveness Analysis By Product type
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Cancer
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) By Cancer, 2019 to 2023
8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Cancer, 2024 to 2034
8.3.1. Breast Cancer
8.3.2. Lung Cancer
8.3.3. Colorectal Cancer
8.3.4. Prostate Cancer
8.3.5. Ovarian Cancer
8.3.6. Hematologic Cancer
8.3.7. Liver Cancer
8.3.8. Pancreatic Cancer
8.3.9. Skin Cancer (Melanoma)
8.3.10. Others
8.4. Market Attractiveness Analysis By Cancer
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) By End User, 2019 to 2023
9.3. Current and Future Market Size (US$ million) Analysis and Forecast By End User, 2024 to 2034
9.3.1. Hospitals
9.3.2. Specialty Centers
9.3.3. Long-term Care Centers
9.3.4. Diagnostic Centers
9.3.5. Academic and Research Institutes
9.4. Market Attractiveness Analysis By End User
10. Global Market Cross Sectional Analysis - Product Type Vs. End User
10.1. Historical Market Size (US$ million) By Product type Vs. End User, 2019 to 2023
10.2. Current and Future Market Size (US$ million) Analysis and Forecast by Product type Vs. End User, 2024 to 2034
10.2.1. In Situ Hybridization (ISH) Test Kits
10.2.1.1. Hospitals
10.2.1.2. Specialty Centers
10.2.1.3. Long-term Care Centers
10.2.1.4. Diagnostic Centers
10.2.1.5. Academic and Research Institutes
10.2.2. Molecular Diagnostics Test Kits
10.2.2.1. Hospitals
10.2.2.2. Specialty Centers
10.2.2.3. Long-term Care Centers
10.2.2.4. Diagnostic Centers
10.2.2.5. Academic and Research Institutes
10.2.3. Companion Diagnostics Test Kits
10.2.3.1. Hospitals
10.2.3.2. Specialty Centers
10.2.3.3. Long-term Care Centers
10.2.3.4. Diagnostic Centers
10.2.3.5. Academic and Research Institutes
10.2.4. Immunohistochemistry (IHC) Test Kits
10.2.4.1. Hospitals
10.2.4.2. Specialty Centers
10.2.4.3. Long-term Care Centers
10.2.4.4. Diagnostic Centers
10.2.4.5. Academic and Research Institutes
11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ million) Trend Analysis by Region, 2019 to 2023
11.3. Current and Future Market Size (US$ million) Analysis and Forecast by Region, 2024 to 2034
11.3.1. North America
11.3.2. Latin America
11.3.3. East Asia
11.3.4. South Asia and Pacific
11.3.5. Western Europe
11.3.6. Eastern Europe
11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis by Region
11.5. Key Market Trends, By Region
12. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
12.1. Introduction
12.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
12.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
12.3.1. By Country
12.3.1.1. United States
12.3.1.2. Canada
12.3.1.3. Mexico
12.3.2. By Product type
12.3.3. By Cancer
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product type
12.4.3. By Cancer
12.4.4. By End User
12.5. Drivers and Restraints Impact Analysis
12.6. Country-Wise Analysis
12.6.1. United States Market Analysis
12.6.1.1. Introduction
12.6.1.2. Market Analysis and Forecast by Market Taxonomy
12.6.1.2.1. By Product type
12.6.1.2.2. By Cancer
12.6.1.2.3. By End User
12.6.2. Canada Market Analysis
12.6.2.1. Introduction
12.6.2.2. Market Analysis and Forecast by Market Taxonomy
12.6.2.2.1. By Product type
12.6.2.2.2. By Cancer
12.6.2.2.3. By End User
12.6.3. Mexico Market Analysis
12.6.3.1. Introduction
12.6.3.2. Market Analysis and Forecast by Market Taxonomy
12.6.3.2.1. By Product type
12.6.3.2.2. By Cancer
12.6.3.2.3. By End User
13. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
13.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Chile
13.3.1.3. Rest of Latin America
13.3.2. By Product type
13.3.3. By Cancer
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product type
13.4.3. By Cancer
13.4.4. By End User
13.5. Drivers and Restraints Impact Analysis
13.6. Country-Wise Analysis
13.6.1. Brazil Market Analysis
13.6.1.1. Introduction
13.6.1.2. Market Analysis and Forecast by Market Taxonomy
13.6.1.2.1. By Product type
13.6.1.2.2. By Cancer
13.6.1.2.3. By End User
13.6.2. Chile Market Analysis
13.6.2.1. Introduction
13.6.2.2. Market Analysis and Forecast by Market Taxonomy
13.6.2.2.1. By Product type
13.6.2.2.2. By Cancer
13.6.2.2.3. By End User
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
14.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Product type
14.3.3. By Cancer
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product type
14.4.3. By Cancer
14.4.4. By End User
14.5. Drivers and Restraints Impact Analysis
14.6. Country-Wise Analysis
14.6.1. China Market Analysis
14.6.1.1. Introduction
14.6.1.2. Market Analysis and Forecast by Market Taxonomy
14.6.1.2.1. By Product type
14.6.1.2.2. By Cancer
14.6.1.2.3. By End User
14.6.2. Japan Market Analysis
14.6.2.1. Introduction
14.6.2.2. Market Analysis and Forecast by Market Taxonomy
14.6.2.2.1. By Product type
14.6.2.2.2. By Cancer
14.6.2.2.3. By End User
14.6.3. South Korea Market Analysis
14.6.3.1. Introduction
14.6.3.2. Market Analysis and Forecast by Market Taxonomy
14.6.3.2.1. By Product type
14.6.3.2.2. By Cancer
14.6.3.2.3. By End User
15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
15.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
15.3.1. By Country
15.3.1.1. India
15.3.1.2. ASEAN Countries
15.3.1.3. Australia and New Zealand
15.3.1.4. Rest of South Asia
15.3.2. By Product type
15.3.3. By Cancer
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product type
15.4.3. By Cancer
15.4.4. By End User
15.5. Drivers and Restraints Impact Analysis
15.6. Country-Wise Analysis
15.6.1. India Market Analysis
15.6.1.1. Introduction
15.6.1.2. Market Analysis and Forecast by Market Taxonomy
15.6.1.2.1. By Product type
15.6.1.2.2. By Cancer
15.6.1.2.3. By End User
15.6.2. ASEAN Countries Market Analysis
15.6.2.1. Introduction
15.6.2.2. Market Analysis and Forecast by Market Taxonomy
15.6.2.2.1. By Product type
15.6.2.2.2. By Cancer
15.6.2.2.3. By End User
15.6.3. Australia and New Zealand Market Analysis
15.6.3.1. Introduction
15.6.3.2. Market Analysis and Forecast by Market Taxonomy
15.6.3.2.1. By Product type
15.6.3.2.2. By Cancer
15.6.3.2.3. By End User
16. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
16.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. United Kingdom
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Nordic Countries
16.3.1.8. Rest of Western Europe
16.3.2. By Product type
16.3.3. By Cancer
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product type
16.4.3. By Cancer
16.4.4. By End User
16.5. Drivers and Restraints Impact Analysis
16.6. Country-Wise Analysis
16.6.1. Germany Market Analysis
16.6.1.1. Introduction
16.6.1.2. Market Analysis and Forecast by Market Taxonomy
16.6.1.2.1. By Product type
16.6.1.2.2. By Cancer
16.6.1.2.3. By End User
16.6.2. Italy Market Analysis
16.6.2.1. Introduction
16.6.2.2. Market Analysis and Forecast by Market Taxonomy
16.6.2.2.1. By Product type
16.6.2.2.2. By Cancer
16.6.2.2.3. By End User
16.6.3. Spain Market Analysis
16.6.3.1. Introduction
16.6.3.2. Market Analysis and Forecast by Market Taxonomy
16.6.3.2.1. By Product type
16.6.3.2.2. By Cancer
16.6.3.2.3. By End User
16.6.4. France Market Analysis
16.6.4.1. Introduction
16.6.4.2. Market Analysis and Forecast by Market Taxonomy
16.6.4.2.1. By Product type
16.6.4.2.2. By Cancer
16.6.4.2.3. By End User
16.6.5. United Kingdom Market Analysis
16.6.5.1. Introduction
16.6.5.2. Market Analysis and Forecast by Market Taxonomy
16.6.5.2.1. By Product type
16.6.5.2.2. By Cancer
16.6.5.2.3. By End User
16.6.6. Spain Market Analysis
16.6.6.1. Introduction
16.6.6.2. Market Analysis and Forecast by Market Taxonomy
16.6.6.2.1. By Product type
16.6.6.2.2. By Cancer
16.6.6.2.3. By End User
16.6.7. BENELUX Market Analysis
16.6.7.1. Introduction
16.6.7.2. Market Analysis and Forecast by Market Taxonomy
16.6.7.2.1. By Product type
16.6.7.2.2. By Cancer
16.6.7.2.3. By End User
16.6.8. Nordic Countries Market Analysis
16.6.8.1. Introduction
16.6.8.2. Market Analysis and Forecast by Market Taxonomy
16.6.8.2.1. By Product type
16.6.8.2.2. By Cancer
16.6.8.2.3. By End User
17. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
17.1. Introduction
17.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
17.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
17.3.1. By Country
17.3.1.1. Russia
17.3.1.2. Hungary
17.3.1.3. Poland
17.3.1.4. Rest of Eastern Europe
17.3.2. By Product type
17.3.3. By Cancer
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product type
17.4.3. By Cancer
17.4.4. By End User
17.5. Drivers and Restraints Impact Analysis
17.6. Country-Wise Analysis
17.6.1. Russia Market Analysis
17.6.1.1. Introduction
17.6.1.2. Market Analysis and Forecast by Market Taxonomy
17.6.1.2.1. By Product type
17.6.1.2.2. By Cancer
17.6.1.2.3. By End User
17.6.2. Hungary Market Analysis
17.6.2.1. Introduction
17.6.2.2. Market Analysis and Forecast by Market Taxonomy
17.6.2.2.1. By Product type
17.6.2.2.2. By Cancer
17.6.2.2.3. By End User
17.6.3. Poland Market Analysis
17.6.3.1. Introduction
17.6.3.2. Market Analysis and Forecast by Market Taxonomy
17.6.3.2.1. By Product type
17.6.3.2.2. By Cancer
17.6.3.2.3. By End User
18. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034
18.1. Introduction
18.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
18.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
18.3.1. By Country
18.3.1.1. Saudi Arabia
18.3.1.2. Türkiye
18.3.1.3. South Africa
18.3.1.4. Other African Union
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Product type
18.3.3. By Cancer
18.3.4. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product type
18.4.3. By Cancer
18.4.4. By End User
18.5. Drivers and Restraints Impact Analysis
18.6. Country-Wise Analysis
18.6.1. Saudi Arabia Market Analysis
18.6.1.1. Introduction
18.6.1.2. Market Analysis and Forecast by Market Taxonomy
18.6.1.2.1. By Product type
18.6.1.2.2. By Cancer
18.6.1.2.3. By End User
18.6.2. Türkiye Market Analysis
18.6.2.1. Introduction
18.6.2.2. Market Analysis and Forecast by Market Taxonomy
18.6.2.2.1. By Product type
18.6.2.2.2. By Cancer
18.6.2.2.3. By End User
18.6.3. South Africa Market Analysis
18.6.3.1. Introduction
18.6.3.2. Market Analysis and Forecast by Market Taxonomy
18.6.3.2.1. By Product type
18.6.3.2.2. By Cancer
18.6.3.2.3. By End User
18.6.4. Other African Union Market Analysis
18.6.4.1. Introduction
18.6.4.2. Market Analysis and Forecast by Market Taxonomy
18.6.4.2.1. By Product type
18.6.4.2.2. By Cancer
18.6.4.2.3. By End User
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players (%)
19.3. Market Presence Analysis
19.3.1. Regional footprint of Players
19.3.2. Product foot print by Players
19.3.3. Channel Foot Print by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Branding and Promotional Strategies, By Key Manufactures
20.4. Key Development Analysis
20.5. Competition Deep Dive
20.5.1. Abbott Laboratories
20.5.1.1. Overview
20.5.1.2. Product Portfolio
20.5.1.3. Key Financials
20.5.1.4. SWOT Analysis
20.5.1.5. Key Developments
20.5.1.6. Sales Footprint
20.5.1.7. Strategy Overview
20.5.1.7.1. Marketing Strategy
20.5.1.7.2. Product Strategy
20.5.1.7.3. Channel Strategy
20.5.2. F.Hoffmann-La Roche Ltd.
20.5.3. Thermo Fisher Scientific Inc.
20.5.4. Merck KGaA (Sigma-Aldrich Co., LLC)
20.5.5. Danaher Corporation (Cepheid)
20.5.6. Agilent Technologies, Inc.
20.5.7. Quest Diagnostics Incorporated
20.5.8. Bio Rad Laboratories Inc.
20.5.9. QIAGEN
20.5.10. Illumina, Inc.
20.5.11. Enzo Life Sciences, Inc.
20.5.12. BioGenex
20.5.13. Bio SB
20.5.14. Nanoprobes, Inc.
20.5.15. Creative Biolabs.
20.5.16. Takara Bio Inc.
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Cancer Tissue Diagnostic Market
